In a 50-patient trial conducted by Hofman et al using LuPSMA alone against mCRPC, median OS was 13.3 months.
Median OS in the 56-patient LuPIN trial using LuPSMA + NOX66 was 19.7 months.
There was one significant difference: the LuPIN patients were MORE resistant to treatment, having had to have failed more prior therapies.
The LuPIN result was indeed remarkable.
- Forums
- ASX - By Stock
- Ann: LuPIN Survival Outcome Confirmed by Conference Presentation
In a 50-patient trial conducted by Hofman et al using LuPSMA...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 72463 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 8810 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 72463 | 0.069 |
3 | 22705 | 0.068 |
1 | 1672 | 0.066 |
1 | 15000 | 0.065 |
1 | 15626 | 0.064 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 8810 | 1 |
0.073 | 77931 | 2 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
Last trade - 10.16am 29/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
Day chart unavailable